HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress

Reuters

10/13

HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress

HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575457425"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575457425\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575457425?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575457425","market":"nz","top_or_hot":-1,"title":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL2ngkDW:1","article_id":"2575457425","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575457425","pubTimestamp":1760328199,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress. HUTCHMED  Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","00013":"和黄医药","BK1191":"制药","BK1587":"次新股"},"translate_title":"和黄医药宣布呋喹替尼和信迪利单抗组合治疗晚期肾细胞癌的FRUSICA-2试验结果积极；数据将在2025年ESMO大会上公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9},"content_text":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    \n\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}